2023
Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality
Zhou J, pour A, Deirawan H, Daaboul F, Aung T, Beydoun R, Ahmed F, Chuang J. Integrative deep learning analysis improves colon adenocarcinoma patient stratification at risk for mortality. EBioMedicine 2023, 94: 104726. PMID: 37499603, PMCID: PMC10388166, DOI: 10.1016/j.ebiom.2023.104726.Peer-Reviewed Original ResearchConceptsModerate-risk patientsClinical variablesPatient stratificationOverall survivalAdenocarcinoma patientsTCGA-COADLow-risk patientsColorectal cancer patientsEnrollment of patientsRectal adenocarcinoma patientsRisk of mortalityColon adenocarcinoma patientsLow immune infiltrationNational Cancer InstituteMutation signaturesNumber of deathsCancer Genome AtlasColorectal cancerPathological featuresCancer patientsImmune infiltrationImproved stratificationClinical trialsPatient riskCancer Institute
2021
Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer Recurrence
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial CancerSex Hormones and Insulin in Endometrial Cancer Recurrence. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 719-726. PMID: 33622671, PMCID: PMC8026669, DOI: 10.1158/1055-9965.epi-20-1613.Peer-Reviewed Original ResearchConceptsEndometrial cancer recurrenceSex hormonesEndometrial cancerProgesterone receptorCancer recurrenceInsulin/insulin-like growth factor axisRecurrence riskInsulin-like growth factor (IGF) axisInsulin-like growth factorGynecologic Oncology GroupProgression-free survivalEndometrial adenocarcinoma patientsIGF-binding proteinsFuture clinical trialsGrowth factor axisConfidence intervalsIR/IGF1RAdjuvant therapyER positivityIGFBP-3Oncology GroupProspective cohortAdenocarcinoma patientsPretreatment specimensSerum concentrations
2019
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment
Mills B, Connolly K, Ye J, Murphy J, Uccello T, Han B, Zhao T, Drage M, Murthy A, Qiu H, Patel A, Figueroa N, Johnston C, Prieto P, Egilmez N, Belt B, Lord E, Linehan D, Gerber S. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment. Cell Reports 2019, 29: 406-421.e5. PMID: 31597100, PMCID: PMC6919969, DOI: 10.1016/j.celrep.2019.08.095.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyMultiple preclinical mouse modelsPancreatic ductal adenocarcinoma patientsEffective neoadjuvant therapyAdvanced metastatic diseaseStereotactic body radiationDuctal adenocarcinoma patientsLate-stage diseaseInterferon-gamma productionBody radiation therapySystemic tumor immunityPreclinical mouse modelsNeoadjuvant approachNeoadjuvant therapyLiver metastasesMetastatic diseaseCD8 TTumor immunityAdenocarcinoma patientsImmune microenvironmentTumor reductionMS administrationTherapy resultsPancreatic tumorsGamma production
2018
P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original ResearchLung adenocarcinoma patientsAdjuvant chemotherapyStage IAAdenocarcinoma patientsChemotherapyPatientsEffect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.
Shitara K, Shah M, Di Bartolomeo M, Lonardi S, Al-Batran S, Van Cutsem E, Ilson D, Chau I, Alsina M, Lacy J, Takahari D, Sugimoto N, Bendell J, Wainberg Z, Tehfe M, Ferry D, Wei R, Walgren R, Das M, Fuchs C. Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis. Journal Of Clinical Oncology 2018, 36: 4044-4044. DOI: 10.1200/jco.2018.36.15_suppl.4044.Peer-Reviewed Original Research
2017
Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
Thaler J, Sigel C, Beasley MB, Wisnivesky J, Crothers K, Bauml J, Hysell K, Emu B, Borsu L, Sigel K. Clinically significant mutations in HIV-infected patients with lung adenocarcinoma. British Journal Of Cancer 2017, 117: 1392-1395. PMID: 28934759, PMCID: PMC5672933, DOI: 10.1038/bjc.2017.333.Peer-Reviewed Original ResearchConceptsPrevalence of eGFRHIV statusKRAS mutationsLung adenocarcinomaMutation statusLung adenocarcinoma patientsPresence of KRASUninfected comparatorsOverall survivalAdenocarcinoma patientsTumor EGFRLung cancerMutational testingPatientsMajor causeEGFRPrevalenceGenetic alterationsHIVAdenocarcinomaSignificant mutationsStatusSurvivalMutationsSubjects
2016
Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma
Sekigami Y, Rajeev R, Johnston F, Clark Gamblin T, Turaga K. Conditional Survival as a Patient Centered Metric for Patients with Appendiceal Adenocarcinoma. Annals Of Surgical Oncology 2016, 23: 2295-2301. PMID: 26856719, DOI: 10.1245/s10434-016-5105-7.Peer-Reviewed Original ResearchConceptsAppendiceal adenocarcinomaMetastatic diseaseOverall survivalFive-year overall survivalConditional survivalCumulative probability of survivalActuarial life table analysisKaplan-Meier curvesSignet ring cellsLife table analysisExtended surgeryMucinous adenocarcinomaMedian ageAdenocarcinoma patientsPatients' better understandingFollow-upAdenocarcinomaProbability of survivalRing cellsBurden of diseasePatientsSurveillance strategiesNature of therapyNOSSurvival
2012
Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing
Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer J, Legendre C, Posner R, Hostetter G, Baker A, Egan J, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Von Hoff D. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing. PLOS ONE 2012, 7: e43192. PMID: 23071490, PMCID: PMC3468610, DOI: 10.1371/journal.pone.0043192.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBase SequenceBRCA2 ProteinDNA RepairFemaleGene DosageGenome, HumanHigh-Throughput Nucleotide SequencingHumansMaleMetabolic Networks and PathwaysPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins c-mycProto-Oncogene Proteins p21(ras)ras ProteinsSequence Analysis, RNATranscriptomeTumor Suppressor Protein p53ConceptsPancreatic adenocarcinoma patientsNext generation sequencingPancreatic adenocarcinomaGeneration sequencingSomatic eventsGenome-wide characterizationChromosomal copy number variantsCopy number variantsImproved therapeutic selectivityTumor suppressive pathwaysPancreatic adenocarcinoma tumorigenesisTumor-stroma interactionsKRAS signaling pathwaySequence dataTranscriptomic informationTumor/normal samplesEvaluate expression changesTranslocation eventsMultiple genesPoint mutationsRNA sequencingMapped readsPatient tumorsAdenocarcinoma patientsPathway analysisCpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis
Fu T, Pappou EP, Guzzetta AA, Jeschke J, Kwak R, Dave P, Hooker CM, Morgan R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. CpG Island Methylator Phenotype–Positive Tumors in the Absence of MLH1 Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis. Clinical Cancer Research 2012, 18: 4743-4752. PMID: 22825585, PMCID: PMC3482463, DOI: 10.1158/1078-0432.ccr-12-0707.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinomaAgedCpG IslandsDNA MethylationDuodenal NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMicrosatellite InstabilityMiddle AgedMutL Protein Homolog 1Nuclear ProteinsPrognosisProportional Hazards ModelsProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsConceptsMLH1 methylation statusDuodenal adenocarcinomaMicrosatellite instabilityPoor prognosisBRAF mutationsMLH1 methylationCox proportional hazards modelDuodenal adenocarcinoma patientsKaplan-Meier analysisSignificant prognostic valueCpG island methylator phenotype (CIMP) statusProportional hazards modelBRAF V600E mutationMethylation statusWorse OSOverall survivalClinicopathologic featuresTumor characteristicsAdenocarcinoma patientsPrognostic valueKRAS mutationsMSI statusHazards modelAdenocarcinomaV600E mutationAbstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing
Liang W, Craig D, Carpten J, Borad M, Demeure M, Weiss G, Kiefer J, Posner R, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Baker A, Han H, Lake D, Stites E, Ramanathan R, Fonseca R, Stewart A, Hoff D. Abstract 5104: Identification of key tumorigenic pathways in pancreatic adenocarcinoma patients using massively parallel DNA and RNA sequencing. Cancer Research 2012, 72: 5104-5104. DOI: 10.1158/1538-7445.am2012-5104.Peer-Reviewed Original ResearchNext-generation sequencing technologiesWhole-genome sequencingWhole-transcriptome sequencingPancreatic adenocarcinoma patientsChromosomal copy number variantsMassively parallel DNACopy number variantsPancreatic cancer pathwayAdenocarcinoma patientsPancreatic adenocarcinomaGlobal pathway analysisGenome sequenceSequencing technologiesTranscriptome sequencingPinpointing genesAmerican Association for Cancer ResearchKRAS signaling pathwayMultiple genesPoint mutationsRNA sequencingParallel DNASomatic eventsPathway analysisSignaling pathwayCancer pathways
2011
Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy
Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research 2011, 71: 5512-5521. PMID: 21724587, PMCID: PMC3159530, DOI: 10.1158/0008-5472.can-10-2614.Peer-Reviewed Original ResearchConceptsCell lung carcinomaHIF-1α levelsAdjuvant therapyLung carcinomaAdjuvant platinum-based chemotherapyVEGFR-2 blockadeNuclear hypoxia inducible factor-1αNSCLC tumor cellsPlatinum-based chemotherapyFavorable overall survivalRisk of deathHypoxia-inducible factor-1αHigher microvessel densityNSCLC tumor specimensNSCLC cell linesInducible factor-1αCell linesVEGF receptor 2Adjuvant chemotherapyOverall survivalClinical outcomesAdenocarcinoma patientsMicrovessel densityShorter survivalHigh riskAssociation of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356).
Bohanes P, Goldman B, Leichman L, Blanke C, Iqbal S, Thomas C, Corless C, Billingsley K, Danenberg K, Zhang W, Benedetti J, Gold P, Lenz H. Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). Journal Of Clinical Oncology 2011, 29: 4023-4023. DOI: 10.1200/jco.2011.29.15_suppl.4023.Peer-Reviewed Original Research
2010
OC-052 Assessment of novel genetic polymorphisms and risk of upper gastrointestinal carcinoma
Hold G, El-Omar E, Chow W, Risch H, Gammon M, Vaughan T, Lissowska J, Lochhead P, Rabkin C, Ng M. OC-052 Assessment of novel genetic polymorphisms and risk of upper gastrointestinal carcinoma. Gut 2010, 59: a21. DOI: 10.1136/gut.2009.208959z.Peer-Reviewed Original ResearchCase-control studyOesophageal cancerGastric cancer case-control studySolid tumorsNon-cardia gastric cancerMajor global health problemUpper GI cancerSquamous cell oesophageal cancerUpper gastrointestinal malignanciesRisk of gastricUpper gastrointestinal carcinomasCancer case-control studyGastric Cancer StudyGastric adenocarcinoma patientsGlobal health problemGastrointestinal malignanciesAdenocarcinoma patientsColorectal cancerGastrointestinal carcinomasGI cancersGastric adenocarcinomaNovel genetic polymorphismsRisk factorsGastric cancerElevated risk
2009
High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma
Anagnostou VK, Bepler G, Syrigos KN, Tanoue L, Gettinger S, Homer RJ, Boffa D, Detterbeck F, Rimm DL. High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma. Clinical Cancer Research 2009, 15: 4157-4164. PMID: 19509151, DOI: 10.1158/1078-0432.ccr-09-0099.Peer-Reviewed Original ResearchConceptsLung cancer patientsMTOR expressionCancer patientsMammalian targetEarly-stage lung adenocarcinomaHigh mTOR expressionIndependent lower riskMedian overall survivalStage IA patientsProtein expressionSubgroup of patientsLung adenocarcinoma patientsStage lung adenocarcinomaMTOR protein expressionRole of mTOROverall survivalPathologic characteristicsPatient survivalValidation cohortAdenocarcinoma groupAdenocarcinoma patientsPrognostic stratificationLung cancerTraining cohortFavorable outcome
2005
High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor
Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. Cancer Research 2005, 65: 11478-11485. PMID: 16357156, DOI: 10.1158/0008-5472.can-05-1977.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma, Bronchiolo-AlveolarAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsGefitinibGenes, rasHumansLigandsLung NeoplasmsMiceMice, KnockoutMutationNeoplasms, Glandular and EpithelialPhosphorylationProto-Oncogene Proteins c-aktQuinazolinesReceptor, ErbB-2Receptor, ErbB-3Tumor Cells, CulturedTyrosineConceptsEpidermal growth factor receptorLung adenocarcinoma patientsLung adenocarcinoma cellsErbB family membersEGFR inhibitionGrowth factor receptorAdenocarcinoma patientsLung adenocarcinomaTumor biopsiesAdenocarcinoma cellsEpithelial neoplastic lesionsHigh expressionFactor receptorGenetic mutationsHuman lung adenocarcinoma cell lineLung adenocarcinoma cell linesAdenocarcinoma cell lineFamily membersNeoplastic lesionsOncogenic KrasErbB ligandsReceptorsAdenocarcinomaPatientsBiopsyDemographic and lifestyle predictors of survival in patients with esophageal or gastric cancers
Trivers KF, de Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH. Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clinical Gastroenterology And Hepatology 2005, 3: 225-230. PMID: 15765441, DOI: 10.1016/s1542-3565(04)00613-5.Peer-Reviewed Original ResearchConceptsBody mass indexEsophageal squamous cell carcinomaGastric cancerHazard ratioLonger survivalNonsteroidal anti-inflammatory drug usePopulation-based case-control studyAnti-inflammatory drug usePrediagnosis body mass indexAdjusted hazard ratioGastroesophageal reflux diseaseSquamous cell carcinomaConfidence intervalsGastric cancer survivalCase-control studyEsophageal adenocarcinoma patientsLocalized diseaseReflux diseaseMass indexAlcohol intakeCigarette smokingDecreased riskIncident casesAdenocarcinoma patientsCell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply